about
DNA Nanotechnology for Cancer TherapyPrognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-AnalysisThe prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancerDevelopment and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic studyAssociation of theHLA-G3′UTR polymorphisms with colorectal cancer in Italy: a first insight2-D gel electrophoresis: constructing 2D-gel proteome reference maps.Pharmacogenetics of irinotecan.Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometry.Galectin-10, eosinophils, and celiac disease.PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage.MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer.Fluorescent carbon nanoparticles in medicine for cancer therapyNucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets.DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease.Overexpression of folate binding protein in ovarian cancers.Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy.Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel.New oral drugs in older patients: a review of idarubicin in elderly patients.Pharmacokinetic optimisation of treatment with oral etoposide.HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.Pharmacogenomics and stomach cancer.Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.Pharmacokinetics of doxorubicin co-administered with high-dose verapamilNon-linear pharmacokinetics of high-dose intravenous verapamilCyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model.Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma.Androgen receptor serine 81 mediates Pin1 interaction and activity.Is tailored therapy feasible in oncology?Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.pRb controls estrogen receptor alpha protein stability and activity.UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review.
P50
Q26750363-F6F6BC3C-84EF-4B6F-A981-EA3C93ED0959Q26785421-1C031884-4740-461A-8A05-F3E50B60642EQ28485944-87ED04CE-B8FB-4E8F-9D3F-F3B57B477FD0Q28543429-DA59AAF1-3FFC-4C2C-B163-85DD73ADC1A6Q29030926-2E9C8200-C1F2-480C-8705-F4552C718E44Q31042678-24267CAD-8F7C-4548-A863-0721D5D5DFB0Q33348193-099412DB-9832-4636-8818-9205A869D92BQ33439123-C53E0B84-7D15-4827-996C-4DD86BB665E2Q33503849-79DE0F3D-D0CB-44A9-8D9B-5C1AF588F296Q33573305-17E10407-2553-4C80-8FF8-550C5E1B602FQ33579778-767D75E4-A3A5-48B1-8D38-7E810F0DE4FEQ33618495-CE1F2A3B-18B2-4FD0-A0C2-5F90ACE3F646Q33752901-0162DB6D-B26F-4FA3-AAB6-BF1341587947Q33985880-9B62371E-3C47-45EE-AA7A-0B0FE62DE21BQ34234941-73FB7EE9-EC65-4CDB-AF0D-23D965680118Q34407435-8D4F6D6B-954B-4EE4-975E-C36031334FFCQ34424458-A4D7861B-CBD1-4336-96A9-8ED7D84AA7E6Q34975510-AF4E0AB6-CB57-4B6B-BBF4-A266B1978E7DQ35529674-C8343DFE-BA9C-4DEB-AE50-1FD2FB2ACBD9Q35586677-BD92A744-107C-4EF8-BBEB-68E7F9934D84Q35612651-6A3B3CF2-6588-421A-98AC-8A73278F13D6Q35687709-3B4F4AC9-08C0-42EC-89CB-1321534D2D89Q35771512-AE9B56B5-4BA7-431E-B64B-7A58C5AC03B6Q35860201-4C8534FB-41F2-44FE-BC4D-68F4AF92052AQ35873676-9DF6A2DE-FBB8-4605-B2FD-C464B565C396Q36033002-07878659-F0B1-4086-825A-5DE0047AE41CQ36079867-2435EF1E-690A-457A-B87B-0A411C3A51A6Q36094105-6E1B939B-C0FC-4090-9959-5B61DBBBC35DQ36116213-2E68A6E8-66CC-467C-8680-E958D1AF0E16Q36175547-0710E1BC-BDAF-4EAA-8614-BD068211F082Q36203262-ED62EF6A-E002-457C-BCB7-40B0B3B2F464Q36304172-AC280356-40CC-4D03-8E7F-E3E195C7DEC8Q36336050-2547D0E9-F0F3-4B52-9767-214BAE139E40Q36915163-F70430DC-4D73-483D-A32B-7D815B95F597Q37132236-553644F2-38F6-4880-A123-56D4C925F03FQ37158174-807715AC-8D3F-489E-97CF-F6076E69E03AQ37190172-F8D77A56-B116-4D14-BB0C-84738FA29E1BQ37286470-FB3AC361-BEDE-4D41-B209-7079665F213CQ37330181-799A1A2C-37AC-42C9-A27B-EF0D93113E6EQ37432385-032F5B46-F9A6-4DE8-B152-AC85A0B8AB11
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
G Toffoli
@ast
G Toffoli
@en
G Toffoli
@es
G Toffoli
@nl
G Toffoli
@sl
type
label
G Toffoli
@ast
G Toffoli
@en
G Toffoli
@es
G Toffoli
@nl
G Toffoli
@sl
prefLabel
G Toffoli
@ast
G Toffoli
@en
G Toffoli
@es
G Toffoli
@nl
G Toffoli
@sl
P106
P1153
7004253129
P31
P496
0000-0002-5323-4762